universal cancer vaccine / CancerVAX, UCLA - LARVOL DELTA

CancerVAX Expands Development Pipeline to Include a Universal CAR-T Cell Platform (GlobeNewswire) - "Foundational technology developed by UCLA for the Company’s Universal Cancer Vaccine can be adapted to function as an in-vivo CAR-T cell platform to dramatically lower the cost of CAR-T cell cancer therapies...CancerVAX, Inc...announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies."

Clinical • Oncology

CancerVax Universal Cancer Vaccine Being Developed by UCLA (GlobeNewswire) - "CancerVAX, Inc...announced that its sponsored research program with the University of California Los Angeles ('UCLA') to research and develop a universal cancer vaccine (UCV) is now fully under way....CancerVAX also entered into an agreement with UCLA that gives the Company the exclusive rights to license all intellectual properties and technologies that may result from this research program."

Licensing / partnership • Oncology

CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine (GlobeNewswire) - "CancerVAX...announced that it has recently filed a non-provisional patent application to protect its invention which leverages cutting-edge bioengineering techniques such as CRISPR and mRNA to develop a breakthrough universal cancer vaccine (UCV)....'Our regular utility patent application (nonprovisional) will now allow the USPTO to formally review our invention claims. If any claims are granted, we will have patent protection starting from the October 2021 provisional filing date'."

Patent • Oncology